



Selenium, Trace Elements and Transition Metals in Anticancer Drug Discovery

Guest Editors:

Prof. Dr. Claus Jacob

Division of Bioorganic Chemistry,
School of Pharmacy, Saarland
University, D-66123
Saarbruecken, Germany

Prof. Dr. Jadwiga Handzlik

Department of Technology and
Biotechnology of Drugs, Faculty
of Pharmacy, Jagiellonian
University Medical College,
Medyczna 9, 30-688 Kraków,
Poland

Dr. Małgorzata Anna Marć

Department of Technology and
Biotechnology of Drugs, Faculty
of Pharmacy, Jagiellonian
University Medical College,
Medyczna 9, 30-688 Kraków,
Poland

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

The search for new anticancer drugs and adjuvants in cancer therapy is an important challenge of the pharmaceutical sciences. Many *in vitro* and *in vivo* experimental models demonstrated the efficacy of Se compounds as anticancer agents. Selenocompounds possess the ability to interfere with the redox homeostasis and signalling of cancer cells to produce anticancer effects. Similarly, compounds and/or nanoparticles containing tellurium, cadmium, gold, rhodium and ruthenium have proven also to show anticancer effects. Taking into account their interesting activity, both selenocompounds, trace elements and transition metals are the object of intensive chemical modifications in order to find new active structures that can serve as a potential anticancer drug candidates or adjuvants in the future cancer therapy. In this Special Issue we want to present the recent advances in the drug design and potential pharmacological applications of all these elements. Articles that report the anticancer or cancer MDR reversing activity of novel compounds containing selenium, tellurium, or novel organic complexes of metals from the d-block are welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](https://twitter.com/MDPIpharma)